Weight loss drives Numan revenue

Numan has effectively become a GLP-1 led obesity clinic, not just a broader men’s health subscription business. That shift matters because weight loss plans are the company’s highest priced product, starting at £179 per month, and they bundle medication, clinician oversight, coaching, and repeat lab work into a much larger recurring revenue stream than ED or hair loss. The result is that a new category launched in September 2023 appears to be driving most of the jump from about $37 million revenue in 2023 to over $90 million in 2024.

• The product mix changed because obesity care has much bigger basket size than Numan’s older services. ED and hair loss subscriptions are recurring, but weight loss combines expensive GLP-1 drugs like Wegovy and Mounjaro with coaching, side effect support, and follow up testing, which lifts monthly revenue per patient far above legacy lines.
  1 sacra 2 numan 4 uktech
• This mirrors a broader European pattern. Yazen pivoted fully into weight loss in 2022 and reached about $17.3 million of 2024 revenue on roughly 42,000 active patients, while Manual and Numan both moved from sexual health into GLP-1 care in 2023. In practice, telehealth clinics are following the obesity drug demand curve because it is the fastest growing cash pay category.
  5 sacra
• The tradeoff is that success now depends much more on drug supply and price. Numan owns more of the care journey through its own platform and pharmacy, but larger players are moving in fast. Hims announced its plan to acquire ZAVA in June 2025 to enter major European markets, and Ro linked with NovoCare Pharmacy to offer Wegovy at $499 per month in April 2025.
  1 sacra 7 hims 8 ro

From here, the likely path is deeper specialization in metabolic health. Once weight loss becomes the main revenue engine, the next products naturally cluster around it, including maintenance programs, glucose monitoring, smart scales, hormone care, and women’s health. That makes Numan look less like a single condition telehealth app and more like a chronic care subscription platform built around obesity first.